Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2022 | $1.00 | Outperform → Mkt Perform | SVB Leerink |
| 7/14/2022 | $15.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 2/16/2022 | $14.00 → $9.00 | Outperform | SVB Leerink |
| 2/2/2022 | $6.50 | Speculative Buy → Buy | WBB Securities |
| 9/9/2021 | $14.00 | Outperform | SVB Leerink |
SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00
Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously
SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h
25-NSE - CONTRAFECT Corp (0001478069) (Subject)
8-K - CONTRAFECT Corp (0001478069) (Filer)
10-Q - CONTRAFECT Corp (0001478069) (Filer)